Spero Therapeutics, Inc. (SPRO)
 NASDAQ: SPRO · Real-Time Price · USD
 2.360
 +0.030 (1.29%)
  At close: Oct 30, 2025, 4:00 PM EDT
2.320
 -0.040 (-1.69%)
  After-hours: Oct 30, 2025, 7:53 PM EDT
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $14.19M in the quarter ending June 30, 2025, with 39.15% growth. This brings the company's revenue in the last twelve months to $48.58M, down -58.99% year-over-year. In the year 2024, Spero Therapeutics had annual revenue of $47.98M, down -53.77%.
Revenue (ttm) 
 $48.58M
Revenue Growth 
 -58.99%
P/S Ratio 
 2.67
Revenue / Employee 
 $1,518,000
Employees 
 32
Market Cap 
132.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% | 
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% | 
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% | 
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% | 
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 422.82B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 55.19B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
SPRO News
- 9 days ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 16 days ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire
- 2 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - GlobeNewsWire
- 5 months ago - Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results - Seeking Alpha
- 5 months ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 5 months ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire